Vnitr Lek 2018, 64(3):229-231 | DOI: 10.36290/vnl.2018.032

Aktuální možnosti biologické léčby idiopatických střevních zánětů - editorial

Tomáš Douda
II. interní gastroenterologická klinika LF UK a FN Hradec Králové

Received: February 11, 2018; Published: March 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Douda T. Aktuální možnosti biologické léčby idiopatických střevních zánětů - editorial. Vnitr Lek. 2018;64(3):229-231. doi: 10.36290/vnl.2018.032.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Neurath M. Cytokines in inflammatory bowel disease. Nat Rev Immunol 2014; 14(5): 329-342. Dostupné z DOI: <http://dx.doi.org/10.1038/nri3661>. Go to original source... Go to PubMed...
    2. Dave M, Papadakis KA, Faubion WA Jr. Immunology of inflammatory bowel disease and molecular targets for biologics. Gastroenterol Clin North Am 2014; 43(3): 405-424. Dostupné z DOI: <http://dx.doi.org/10.1016/j.gtc.2014.05.003>. Go to original source... Go to PubMed...
    3. Burisch J, Jess T, Martinato M et al. The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013; 7(4):322-337. Dostupné z DOI: <http://dx.doi.org/10.1016/j.crohns.2013.01.010>. Go to original source... Go to PubMed...
    4. Burisch J, Munkholm P. The epidemiology of inflammatory bowel disease. Scand J Gastroenterol 2015; 50(8): 942-951. Dostupné z DOI: <http://dx.doi.org/10.3109/00365521.2015.1014407>. Go to original source... Go to PubMed...
    5. Bortlík M, Ďuricová D, Kohout P et al. Doporučení pro podávání biologické terapie u idiopatických střevních zánětů: třetí, aktualizované vydání. Gastroent Hepatol 2016; 70(1): 11-26. Dostupné z DOI: <http://dx.doi.org/10.14735/amgh201611>. Go to original source...
    6. Peyrin-Biroulet L, Deltenre P, de Suray N et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6(6): 644-653. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cgh.2008.03.014>. Go to original source... Go to PubMed...
    7. Danese S, Fiorino G, Peyrin-Biroulet L. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann Intern Med 2014; 160(10): 704-711. Dostupné z DOI: <http://dx.doi.org/10.7326/M13-2403>. Go to original source... Go to PubMed...
    8. Soler D, Chapman T, Yang LL et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009; 330(3): 864-875. Dostupné z DOI: <http://dx.doi.org/10.1124/jpet.109.153973>. Go to original source... Go to PubMed...
    9. Sandborn WJ, Colombel JF, Enns R et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353(18): 1912-1925. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa043335>. Erratum in Natalizumab induction and maintenance therapy for Crohn's disease. [N Engl J Med. 2015]. Go to original source... Go to PubMed...
    10. Danese S, Panes H. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology 2014; 147(5): 981-989. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2014.08.044>. Go to original source... Go to PubMed...
    11. von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N Engl J Med 2000; 343(14): 1020-1034. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJM200010053431407>. Go to original source... Go to PubMed...
    12. Colombel JF, Sands BE, Rutgeerts P et al. The safety of vedolizumab for ulcerative colitis and Crohn's disease. Gut 2017; 66(5): 839-851. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2015-311079>. Go to original source... Go to PubMed...
    13. Tillack C, Ehmann LM, Friedrich M et al. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment. Gut 2014; 63(4): 567-577. Dostupné z DOI: <http://dx.doi.org/10.1136/gutjnl-2012-302853>. Go to original source... Go to PubMed...
    14. Sandborn WJ, Gasink C, Gao LL et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367(16): 1519-1528. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1203572>. Go to original source... Go to PubMed...
    15. Kopylov U, Afif W, Cohen A et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn's disease-The McGill experience. J Crohns Colitis 2014; 8(11): 1516-1522. Dostupné z DOI: <http://dx.doi.org/10.1016/j.crohns.2014.06.005>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.